Bebiana Conde

Prof. Bebiana Conde

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Pulmonology
Verified
Journal Article
Open access
BCBebiana Conde
Bebiana Conde
Natália Cruz-MartinsNatália Cruz-Martins
Natália Cruz-Martins
MBM. Brandão
M. Brandão
APAna Clsudia Pimenta
Ana Clsudia Pimenta
JWJ.C. Winck
J.C. Winck
Upper airways (UA) include the nasal cavities, pharynx, and larynx, and its main function is to warm and filter the inspired air. UA dysfunction is in the pathogenesis of various disorders, such as obstructive sleep apnea syndrome (OSAS) and vocal cord dysfunction. In addition, in some neurodegenerative diseases (e.g. Amyotrophic Lateral Sclerosis - ALS), UA dysfunction may also compromise the effective use of ventilatory support (VS). In this context, the endoscopic evaluation of UA may be useful in understanding the OSAS mechanisms, in determining the causes for treatment-induced airway obstruction and even in helping to titrate noninvasive ventilation (NIV) in ALS patients with bulbar or pseudo-bulbar (spastic) dysfunction. Specifically, in OSAS patients, when residual obstructive events persist, although an optimal ventilatory mode has been apparently achieved, along with interface and equipment, the endoscopic evaluation of UA seems to be a valuable tool in understanding its mechanisms, even assisting adjustments to NIV parameters. In addition, it has also been described as being useful in laryngeal response to mechanical in-exsufflation (MI-E) and Exercise-Induced Laryngeal Obstruction (EILO). However, no protocol has yet been published or validated for this. For this reason, a literature review was conducted on UA function and its response to positive pressure and MI-E. Special emphasis has also been given to the current indication for video endoscopy in chronically ventilated patients.

12 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAndreia Filipa Moreira Rodrigues Matas
Andreia Filipa Moreira Rodrigues Matas
NPNuno Filipe Cardoso Pinto
Nuno Filipe Cardoso Pinto
BCBebiana Conde
Bebiana Conde
MPMaria Vaz Patto
Maria Vaz Patto
Background: This study investigates the relationship between sleep patterns and ischemic stroke beyond the predominant focus on obstructive sleep apnea. Through a systematic review of the existing literature, we aim to elucidate the connections between insomnia, sleep duration, cardiovascular factors, and ischemic stroke onset. Methods: We searched databases, including MEDLINE, SciELO, Scopus, and Science Direct, using an adapted PICO framework. Using a search strategy with MeSH words, keywords, and expressions related to insomnia and stroke, we included clinical trials and analytical observational epidemiological studies, comprising cohort, case–control, and cross-sectional studies. Results: Following the initial search, we identified 984 records, with 779 titles and abstracts screened for eligibility after removing duplicates. From these, 63 full-text articles, including 5 in the data synthesis, were reviewed. Our findings highlight a significant correlation between poor sleep quality, extreme sleep durations, and a heightened risk of ischemic stroke, along with established cardiovascular risk factors, such as hypertension, hyperlipidemia, obesity, and diabetes. Conclusions: This systematic review offers a comprehensive analysis of ischemic stroke prevalence and its association with cardiovascular factors, such as hypertension, hyperlipidemia, obesity, and diabetes. It suggests that poor sleep quality and extreme sleep durations, particularly long ones, are linked to a heightened risk of ischemic stroke.

22 May 2019 in Neuroepidemiology
Verified
Journal Article
Closed access
PDF file
BCBebiana Conde
Bebiana Conde
JWJoão Carlos Winck
João Carlos Winck
LALuís Azevedo
Luís Azevedo
Background: Amyotrophic lateral sclerosis (ALS) is a rare and progressive neurodegenerative disease involving the upper and lower motor neurons. It is also the most common and the one with the worst prognosis among the motor neuron diseases (MND). ALS invariably progresses to respiratory failure, which is an essential factor affecting the prognosis of this disease. Its prevalence in the world is heterogeneous and, in many countries, is even unknown, since national registries are not mandatory or comprehensive enough. Worldwide, the ALS/MND prevalence is estimated between 4 and 8 cases per 100,000 inhabitants, but in Portugal the prevalence was never studied. Because ALS and MND are rare diseases, population-based studies are very difficult to perform. In Portugal, there are no systematic patient registries. Objective: We aimed to obtain the best available indirect estimates of ALS/MND prevalence, using a pharmaco-epidemiological approach. Method: We developed a Bayesian multiparameter evidence synthesis model based on nationwide data of riluzole consumption, a drug highly specific for ALS/MND, combined with data from a nationwide hospital administrative database, data from the national institute of statistics, and data from other scientific articles focused on ALS/MND epidemiology, to estimate ALS/MND prevalence in Portugal. Results: We found an estimated ALS/MND prevalence in Portugal steadily increasing from 6.74 per 100,000 inhabitants (Bayesian 95% Credible Interval [95% CI] 5.39–9.37) in 2009 to 10.32 (95% CI 8.27–14.27) in 2016. In 2016, the estimated ALS/MND prevalence was higher in men, 12.08 per 100,000 (9.66–17.15), than in women, 8.56 (6.84–12.32). Regarding age groups, the estimated prevalence per 100,000 inhabitants were, in 2016 for women, 1.19 (0.78–1.85) for the 80 group. For men, the prevalence estimates were 1.90 (1.32–2.84), 12.89 (9.44–19.16), 32.18 (24.91–45.74), 48.85 (38.72–71.40), and 31.27 (21.73–46.41), respectively, for each age group. We also observed a relevant variability across the country, with prevalence estimates, in 2016, of 9.31 cases per 100,000 inhabitants (7.45–12.86) in the Northern region of Portugal, 11.15 (8.9–15.34) in the Centre region, 10.74 (8.6–14.82) in Lisbon and Alentejo regions, and 5.55 (4.35–7.83) in the Algarve region. Conclusion: Overall, and even though we must account for the limitations of the indirect methods and models used for prevalence estimation, we probably have a very high ALS/MND prevalence in Portugal. It would be important to create registries, particularly in rare diseases, for better organization and distribution of healthcare services and resources, particularly at the level of ventilatory support.

14 October 2018 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BCBebiana Conde
Bebiana Conde
Natália Cruz-MartinsNatália Cruz-Martins
Natália Cruz-Martins
IRInês Rodrigues
Inês Rodrigues
APAna Clsudia Pimenta
Ana Clsudia Pimenta
JWJoao Carlos Winck
Joao Carlos Winck
(1) Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative condition, whose bulbar involvement compromises language, swallowing, and airway protection. When oral nutrition is no longer adequate, percutaneous endoscopic gastroscopy (PEG) may be indicated. However, as exact timing is still debatable, we tried to find it. (2) Methods: A prospective cohort study was performed using fiber-optic endoscopic evaluation of swallowing (FEES), functional evaluation scales (ALS Functional Rating Scale-Revised (ALSFRS-R) and bulbar sub-score (ALSFRS-R-B)), lung function tests (like Forced Vital Capacity (FVC), Cough Peak Flow (CPF)) and anthropometric data. (3) Results: Twenty-three patients were enrolled (mean 65.4 ± 9.1 years, 60.9% males), 12 with spinal-onset. During the study period, 58 FEES were performed (1–4/patients). Even before formal the PEG indication, suggestions were given to correct the alterations found. PEG was placed in 12 patients, on average 21.8 months after diagnosis (FVC = 69.9% ± 26.7%, ALSFRS-R-B = 7.7 ± 3.7, ALSFRS-R = 28.9 ± 12.3), and being 91.7% under ventilatory support. ALSFRS-R-B, CPF, FVC, and ALSFRS-R showed significant discriminant ability for PEG placement. Sensitivity and specificity were, respectively, ALSFRS-R-B ≤ 8 (100/90.9), CPF ≤ 205 (83.3), FVC ≤ 74 (83.3/74.2), and ALSFRS-R < 29 (83.3/65.1). (4) Conclusions: FEES provide additional information beyond formal PEG indication. ALSFRS-R-B score ≤ 8 was found as a best functional and noninvasive indicator for PEG performance in ALS patients.

22 December 2025 in Pulmonology
Verified
Journal Article
Open access
CRCarla Ribeiro
Carla Ribeiro
RGRita Gomes
Rita Gomes
ACAlexandra Carreiro
Alexandra Carreiro
AVAna Luísa Vieira
Ana Luísa Vieira
BSBárbara Seabra
Bárbara Seabra
PPPaula Pinto
Paula Pinto
Background: The use of home mechanical ventilation (HMV) has been increasing worldwide, driven by widening of clinical applications and improved patient survival rates. In Portugal, recent data indicate an even faster growth, although national HMV recommendations have remained unchanged for 25 years. Research question: We aimed to provide an update in clinical practice guidelines for HMV in adults, applicable to the Portuguese context, grounded on the latest available evidence and experts' opinion. Study design and methods: A multidisciplinary panel with experience in HMV in the adult population was assembled. A comprehensive literature search was conducted during March 2023 regarding specific topics: equipment, ventilatory modes and interfaces, HMV initiation, follow-up and monitoring, disease specificities (neuromuscular diseases, obesity-hypoventilation syndrome, restrictive chest wall diseases; chronic obstructive pulmonary disease, and other diseases), home mechanical invasive ventilation, and palliative and end of life care. A 2-round Delphi process was conducted to establish consensus among panel members. A minimum agreement threshold of 80% was required. Results: Out of 88 recommendations initially included in the Delphi process, 61 were selected by consensus. Conclusion: Final recommendations grounded in the current level of evidence are outlined, and the key limitations and proposals for future research are discussed.

1 September 2017
Verified
Conference Paper
Closed access
MBMaria Esteves Simões Brandão
Maria Esteves Simões Brandão
MRMariana Rocha
Mariana Rocha
LNLuísa Nascimento
Luísa Nascimento
TGTeresa Gomes
Teresa Gomes
JSJoelma Silva
Joelma Silva
AFAna Luisa Godoy Fernandes
Ana Luisa Godoy Fernandes
Background:Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy, primarily attributable to asbestos exposure. Aim:To report the experience of our centre in the management of MPM. Methods:All consecutive cases of MPM diagnosed in our centre between 2000 and 2016 were retrospectively reviewed. Clinical data were extracted from medical records. Results:During the study period, we identified 28 cases of MPM, 17 (60,7%) male, with median age at diagnosis of 76 years. Patients (Pts) were predominantly non-smokers (67,9%) and 13 (46,4%) reported previous asbestos exposure. Clinical presentation was mainly characterized by indolent dyspnea and constitutional symptoms. The most common radiological findings were unilateral pleural effusion in 21 Pts (75%) and pleural thickening in 16 Pts (57,1%). The average diagnostic delay was 2 months (up to 24 months) and 21 Pts (75%) presented with stage IV (TNM) disease. Epithelioid histologic subtype was identified in 21 Pts (75%). Therapeutic strategies included: prophylactic thoracic radiotherapy in 15 Pts (53,6%); best supportive care in 14 Pts (50%); chemotherapy in 13 Pts (46,4%); and multimodal therapy with extrapleural pneumonectomy in 1 Pt (3,6%).Median overall survival (OS) was 3,5 months (4,9 months in best supportive care group; 7 months in chemotherapy group; 10 months in multimodal therapy group).Two-year survival rate was 11%. Conclusions:In our cohort, MPM mainly affected non-smoking older men, presenting with non-specific symptoms and advanced stage disease. The outcomes were poor (median OS 4,9-10 months) in accordance with the literature. Raising awareness, early recognition and novel treatment options are necessary to improve the outcomes of MPM.